Last reviewed · How we verify
darbepoetin alfa SF
Darbepoetin alfa SF stimulates erythropoiesis by binding to the erythropoietin receptor.
Darbepoetin alfa SF stimulates erythropoiesis by binding to the erythropoietin receptor. Used for Treatment of anemia associated with chronic kidney disease.
At a glance
| Generic name | darbepoetin alfa SF |
|---|---|
| Sponsor | Amgen |
| Drug class | erythropoiesis-stimulating protein |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Darbepoetin alfa SF is an erythropoiesis-stimulating protein that works by binding to the erythropoietin receptor on the surface of erythroid progenitor cells, stimulating their proliferation and differentiation into mature red blood cells. This leads to an increase in red blood cell production and a subsequent increase in hemoglobin levels.
Approved indications
- Treatment of anemia associated with chronic kidney disease
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- darbepoetin alfa SF CI brief — competitive landscape report
- darbepoetin alfa SF updates RSS · CI watch RSS
- Amgen portfolio CI